ARTICLE | Clinical News
Verubecestat: Ph II/III EPOCH discontinued
February 16, 2017 8:31 PM UTC
Merck said it will stop the double-blind, placebo-controlled, international Phase II/III EPOCH trial evaluating once-daily 12 and 40 mg oral verubecestat based on the findings of an external DMC, whic...
BCIQ Company Profiles
BCIQ Target Profiles